BriaCell Therapeutics Corp.BCTXNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank59
5Y CAGR-43.5%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
-43.5%/yr
Long-term compound
Percentile
P59
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 4.58% |
| Q3 2025 | -10.88% |
| Q2 2025 | -18.17% |
| Q1 2025 | 9.84% |
| Q4 2024 | -67.73% |
| Q3 2024 | 16.60% |
| Q2 2024 | 32.24% |
| Q1 2024 | 2.17% |
| Q4 2023 | 30.40% |
| Q3 2023 | -104.74% |
| Q2 2023 | -34.31% |
| Q1 2023 | -13.72% |
| Q4 2022 | -41.32% |
| Q3 2022 | 45.28% |
| Q2 2022 | -87.98% |
| Q1 2022 | -44.92% |
| Q4 2021 | -15.01% |
| Q3 2021 | 73.28% |
| Q2 2021 | -3631.33% |
| Q1 2021 | -173.68% |
| Q4 2020 | 79.75% |
| Q3 2020 | -1655.43% |
| Q2 2020 | 113.32% |
| Q1 2020 | 83.97% |
| Q4 2019 | -43.39% |
| Q3 2019 | 69.95% |
| Q2 2019 | -293.74% |
| Q1 2019 | 51.38% |
| Q4 2018 | 1.41% |
| Q3 2018 | 5.57% |
| Q2 2018 | -42.86% |
| Q1 2018 | 26.95% |
| Q4 2017 | -1510.96% |
| Q3 2017 | 91.84% |
| Q2 2017 | -155.98% |
| Q1 2017 | 9.17% |
| Q4 2016 | -7.97% |
| Q3 2016 | -11.28% |
| Q2 2016 | 13.75% |
| Q1 2016 | -37.93% |